Isosorbidedinitraat Cf (Isosorbide Dinitrate)

Isosorbide dinitrate is converted in the body to nitric oxide, which activates guanylate cyclase in vascular smooth muscle. This raises cyclic GMP levels, causing relaxation of arteries and veins, reducing preload and afterload, and ultimately decreasing the oxygen demand of the heart.

The specific dose of Isosorbidedinitraat Cf is determined by the prescribing clinician based on the patient’s condition, response, and tolerance. Typical regimens may start with a low dose and be titrated, but exact amounts should always follow the prescriber’s instructions.

Safety data for isosorbide dinitrate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and import documentation.

Isosorbidedinitraat Cf belongs to the nitrate class, offering rapid vasodilation and relief of chest pain. Compared with beta‑blockers, it directly reduces preload and afterload rather than heart rate. Unlike calcium‑channel blockers, its effect is primarily mediated by nitric oxide release. Choice of therapy depends on patient profile and tolerance.

Store the product at room temperature, preferably below 25 °C. Keep it in the original packaging to protect from moisture and light. Do not store in humid or excessively hot environments, and keep out of reach of children.

Isosorbidedinitraat Cf can be taken orally as a tablet or placed under the tongue for sublingual absorption. The route chosen depends on the clinical situation and prescriber recommendation. Swallow tablets with water; for sublingual use, allow the tablet to dissolve completely without chewing.

The most serious adverse events include severe hypotension, syncope, and rare allergic reactions such as rash or breathing difficulty. Patients should be advised to seek immediate medical attention if they experience fainting, a sudden drop in blood pressure, or signs of an allergic response.

Contraindications include patients who are currently taking other nitrate preparations, those using phosphodiesterase‑5 inhibitors (e.g., sildenafil), individuals with severe anemia, and patients with uncontrolled hypotension. Clinicians should also avoid use in patients with known hypersensitivity to isosorbide dinitrate.